🏛️ Verified NIH Record • Updated 2026-01-26
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs (NCT04711135)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Advanced Accelerator Applications
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
Who can join: Review the eligibility criteria below.
Location: University of Kentucky — Lexington, Kentucky
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- University of Kentucky — Lexington, Kentucky
- Cincinnati Children's Hospital — Cincinnati, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Centre Léon Berard — Lyon,
- Maria Sklodowska-Curie National Research Institute of Oncology — Gliwice,
- Hospital Universitari Vall d'Hebron — Barcelona,
- University College Hospital of London — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.